STRADEFY BIOSCIENCES
a New Haven-based drug discovery and development company
STRADEFY BIOSCIENCES
a New Haven-based drug discovery and development company
Our Mission
Stradefy Biosciences is pioneering next-generation bioadhesive drug carriers (BDCs), rationally engineered for cellular bioadhesion, uptake and therapeutic payload release, at levels well beyond seen with antibody drug conjugates (ADCs).. Lead candidates, initially targeting unmet needs in the oncology and immunology areas, have demonstrated in vivo proof of efficacy and are advancing to the IND stage. Stradefy was co-founded by Mark Saltzman, Michael Girardi, Yale University and Elm Street Ventures.
Our Research
Improved i.p. drug delivery with bioadhesive nanoparticles
https://www.pnas.org/doi/10.1073/pnas.1523141113
Nonsurgical treatment of skin cancer with local delivery of bioadhesive nanoparticles https://www.pnas.org/doi/10.1073/pnas.2020575118